High efficacy and low early mortality in high-volume center tricuspid valve surgery.
Julia GötteZittermann ArminRene SchrammSabine BleizifferMarcus-Andre DeutschAndre RennerJan F GummertPublished in: The Thoracic and cardiovascular surgeon (2023)
Our high-volume center data indicate substantially lower than predicted 30-day mortality in different cardiac surgical risk scoring groups. The majority of patients had zero to minimal residual tricuspid valve insufficiency postoperatively. Randomized controlled trials are needed to compare tricuspid valve functional results and long-term outcomes of surgical versus interventional procedures in patients undergoing isolated tricuspid valve procedures.
Keyphrases
- aortic valve
- mitral valve
- aortic stenosis
- ejection fraction
- transcatheter aortic valve replacement
- left ventricular
- patients undergoing
- randomized controlled trial
- cardiovascular events
- minimally invasive
- end stage renal disease
- newly diagnosed
- coronary artery disease
- systematic review
- type diabetes
- prognostic factors
- clinical trial
- big data
- heart failure
- cardiovascular disease
- coronary artery bypass
- study protocol
- percutaneous coronary intervention